Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Limited develops pharmaceutical dosages including generic doses in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.[1]
- Market Cap ₹ 59.0 Cr.
- Current Price ₹ 50.4
- High / Low ₹ 159 / 50.4
- Stock P/E 24.6
- Book Value ₹ 23.3
- Dividend Yield 0.00 %
- ROCE 16.6 %
- ROE 19.9 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.4% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 241 days.
- Working capital days have increased from 179 days to 252 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
31.49 | 25.05 | 20.98 | 22.15 | 25.27 | |
30.14 | 23.41 | 19.78 | 20.29 | 20.53 | |
Operating Profit | 1.35 | 1.64 | 1.20 | 1.86 | 4.74 |
OPM % | 4.29% | 6.55% | 5.72% | 8.40% | 18.76% |
0.09 | 0.01 | 0.21 | 0.82 | 0.02 | |
Interest | 0.46 | 0.48 | 0.47 | 0.61 | 0.65 |
Depreciation | 0.77 | 0.68 | 0.68 | 0.71 | 0.72 |
Profit before tax | 0.21 | 0.49 | 0.26 | 1.36 | 3.39 |
Tax % | 47.62% | 40.82% | 61.54% | 28.68% | 28.91% |
0.10 | 0.30 | 0.09 | 0.97 | 2.40 | |
EPS in Rs | 0.17 | 0.50 | 0.15 | 1.62 | 2.79 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 0% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 100% |
TTM: | 147% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
Last Year: | 20% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 6.00 | 6.00 | 6.00 | 6.00 | 8.60 | 11.70 |
Reserves | 1.11 | 1.47 | 1.56 | 2.98 | 6.58 | 15.61 |
8.27 | 9.59 | 10.24 | 11.79 | 12.66 | 12.88 | |
10.44 | 9.28 | 9.27 | 11.82 | 10.75 | 8.80 | |
Total Liabilities | 25.82 | 26.34 | 27.07 | 32.59 | 38.59 | 48.99 |
11.28 | 11.35 | 11.29 | 10.87 | 10.35 | 10.39 | |
CWIP | 0.06 | 0.00 | 0.00 | 0.00 | 0.15 | 0.15 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
14.48 | 14.99 | 15.78 | 21.72 | 28.09 | 38.45 | |
Total Assets | 25.82 | 26.34 | 27.07 | 32.59 | 38.59 | 48.99 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
1.58 | -1.16 | 0.04 | -0.58 | -3.69 | |
-0.45 | -0.02 | -0.59 | -0.28 | -0.33 | |
-0.55 | 1.27 | 0.18 | 0.94 | 4.01 | |
Net Cash Flow | 0.58 | 0.09 | -0.37 | 0.07 | -0.01 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 63.98 | 109.72 | 108.73 | 177.47 | 241.21 |
Inventory Days | 101.47 | 61.22 | 128.47 | 225.01 | 244.39 |
Days Payable | 225.45 | 161.56 | 198.97 | 329.82 | 281.81 |
Cash Conversion Cycle | -60.01 | 9.38 | 38.24 | 72.66 | 203.80 |
Working Capital Days | 34.66 | 83.35 | 121.61 | 163.30 | 251.61 |
ROCE % | 5.98% | 4.19% | 10.22% | 16.62% |
Documents
Announcements
-
Investor Presentation
23 November 2024 - Medicamen Organics Limited has informed about Investor Presentation
-
Press Release
21 November 2024 - Medicamen Organics Limited has informed regarding a press release dated November 21, 2024, titled "Press Release - Medicamen Organics Secures ₹ 6.28 Cr Order for …
-
Analysts/Institutional Investor Meet/Con. Call Updates
20 November 2024 - Medicamen Organics Limited has informed about Link of Recording
-
Analysts/Institutional Investor Meet/Con. Call Updates
19 November 2024 - Medicamen Organics Limited has informed about Link of Recording
-
Press Release
18 November 2024 - Medicamen Organics Limited has informed regarding a press release dated November 18, 2024, titled "Medicamen Organics Reports 49% Total Revenue Increase in H1 FY25".
Annual reports
Concalls
-
Oct 2024TranscriptNotesPPT
Product Portfolio[1] Their product list comprises 84 products with a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS).